Image Ben Hargreaves R&D Mpox is on the rise again as outbreak gathers pace The original mpox outbreak began in 2022, but case numbers have rumbled on, despite countermeasures. Market Access Drug pricing overhaul sparks tension with industry Up until recently, political rhetoric targeting the pharma industry had been largely all bark and no bite. R&D Drug repositioning to bring forgotten assets from shelves to... A problem very rarely spoken about is the treatments that are promising, but are not developed further. Patients Power to the patients: Patient organisations enabling drug d... Drug development is a complex process and there are many stakeholders involved in bringing treatments to patients. Load more results
R&D Mpox is on the rise again as outbreak gathers pace The original mpox outbreak began in 2022, but case numbers have rumbled on, despite countermeasures.
Market Access Drug pricing overhaul sparks tension with industry Up until recently, political rhetoric targeting the pharma industry had been largely all bark and no bite.
R&D Drug repositioning to bring forgotten assets from shelves to... A problem very rarely spoken about is the treatments that are promising, but are not developed further.
Patients Power to the patients: Patient organisations enabling drug d... Drug development is a complex process and there are many stakeholders involved in bringing treatments to patients.
Digital Chaos & opportunity: Dr Adam Brown unpacks US health policy Dive into our video interview with Dr Adam Brown as he unpacks the chaos and opportunity shaping US health policy.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face